NO20080612L - Immunokonjugatpreparater - Google Patents
ImmunokonjugatpreparaterInfo
- Publication number
- NO20080612L NO20080612L NO20080612A NO20080612A NO20080612L NO 20080612 L NO20080612 L NO 20080612L NO 20080612 A NO20080612 A NO 20080612A NO 20080612 A NO20080612 A NO 20080612A NO 20080612 L NO20080612 L NO 20080612L
- Authority
- NO
- Norway
- Prior art keywords
- immunoconjugate
- formulation
- substantially free
- present
- provides
- Prior art date
Links
- 229940127121 immunoconjugate Drugs 0.000 title abstract 8
- 238000009472 formulation Methods 0.000 abstract 7
- 239000000203 mixture Substances 0.000 abstract 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 abstract 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 abstract 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 abstract 2
- 229930006000 Sucrose Natural products 0.000 abstract 2
- 239000007864 aqueous solution Substances 0.000 abstract 2
- 239000002245 particle Substances 0.000 abstract 2
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 2
- 239000011780 sodium chloride Substances 0.000 abstract 2
- 239000005720 sucrose Substances 0.000 abstract 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 1
- 239000004471 Glycine Substances 0.000 abstract 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 abstract 1
- 229920001213 Polysorbate 20 Polymers 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 abstract 1
- -1 cyclodextrol Chemical compound 0.000 abstract 1
- 239000008121 dextrose Substances 0.000 abstract 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 abstract 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 abstract 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 abstract 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 abstract 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 abstract 1
- 229940068977 polysorbate 20 Drugs 0.000 abstract 1
- 229920000053 polysorbate 80 Polymers 0.000 abstract 1
- 229940068968 polysorbate 80 Drugs 0.000 abstract 1
- 229960004793 sucrose Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6863—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from stomach or intestines cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Communicable Diseases (AREA)
- Inorganic Chemistry (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US70490205P | 2005-08-03 | 2005-08-03 | |
| US70716205P | 2005-08-11 | 2005-08-11 | |
| US74645406P | 2006-05-04 | 2006-05-04 | |
| US74645606P | 2006-05-04 | 2006-05-04 | |
| PCT/US2006/030295 WO2007019232A2 (fr) | 2005-08-03 | 2006-08-02 | Formulations d'immunoconjugué |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20080612L true NO20080612L (no) | 2008-04-30 |
Family
ID=37727890
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20080612A NO20080612L (no) | 2005-08-03 | 2008-02-01 | Immunokonjugatpreparater |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US9114179B2 (fr) |
| EP (1) | EP1917030A4 (fr) |
| JP (3) | JP2009503105A (fr) |
| KR (1) | KR101566393B1 (fr) |
| AU (1) | AU2006278573A1 (fr) |
| BR (1) | BRPI0614100A2 (fr) |
| CA (1) | CA2615122A1 (fr) |
| EA (1) | EA014513B1 (fr) |
| EC (1) | ECSP088159A (fr) |
| IL (1) | IL188733A (fr) |
| MX (1) | MX336033B (fr) |
| NO (1) | NO20080612L (fr) |
| NZ (3) | NZ623901A (fr) |
| WO (1) | WO2007019232A2 (fr) |
Families Citing this family (113)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7138262B1 (en) | 2000-08-18 | 2006-11-21 | Shire Human Genetic Therapies, Inc. | High mannose proteins and methods of making high mannose proteins |
| AU2002311919B8 (en) | 2001-05-11 | 2007-03-22 | Ludwig Institute For Cancer Research Ltd | Specific binding proteins and uses thereof |
| US20100056762A1 (en) | 2001-05-11 | 2010-03-04 | Old Lloyd J | Specific binding proteins and uses thereof |
| US20160279239A1 (en) | 2011-05-02 | 2016-09-29 | Immunomedics, Inc. | Subcutaneous administration of anti-cd74 antibody for systemic lupus erythematosus and autoimmune disease |
| US8658773B2 (en) | 2011-05-02 | 2014-02-25 | Immunomedics, Inc. | Ultrafiltration concentration of allotype selected antibodies for small-volume administration |
| US20110166319A1 (en) * | 2005-02-11 | 2011-07-07 | Immunogen, Inc. | Process for preparing purified drug conjugates |
| US20160355591A1 (en) | 2011-05-02 | 2016-12-08 | Immunomedics, Inc. | Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies |
| CA3000520C (fr) | 2005-08-24 | 2023-04-04 | Immunogen, Inc. | Procede de preparation de conjugues maytansinoides-anticorps |
| US8759297B2 (en) | 2006-08-18 | 2014-06-24 | Armagen Technologies, Inc. | Genetically encoded multifunctional compositions bidirectionally transported between peripheral blood and the cns |
| US7767206B2 (en) | 2006-10-02 | 2010-08-03 | Amgen Inc. | Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto |
| US9090693B2 (en) * | 2007-01-25 | 2015-07-28 | Dana-Farber Cancer Institute | Use of anti-EGFR antibodies in treatment of EGFR mutant mediated disease |
| CA2680854C (fr) * | 2007-03-15 | 2017-02-14 | Ludwig Institute For Cancer Research | Procede de traitement utilisant des anticorps d'egfr et des inhibiteurs de src, et formulations en rapport |
| AU2008282496B2 (en) | 2007-07-27 | 2013-04-04 | Armagen Technologies, Inc. | Methods and compositions for increasing alpha-iduronidase activity in the CNS |
| CN108424454B (zh) | 2007-08-14 | 2022-05-31 | 路德维格癌症研究所有限公司 | 靶向egf受体的单克隆抗体175及其衍生物和用途 |
| US8883146B2 (en) | 2007-11-30 | 2014-11-11 | Abbvie Inc. | Protein formulations and methods of making same |
| PE20091174A1 (es) | 2007-12-27 | 2009-08-03 | Chugai Pharmaceutical Co Ltd | Formulacion liquida con contenido de alta concentracion de anticuerpo |
| US8454960B2 (en) | 2008-01-03 | 2013-06-04 | The Scripps Research Institute | Multispecific antibody targeting and multivalency through modular recognition domains |
| KR101658247B1 (ko) | 2008-01-03 | 2016-09-22 | 더 스크립스 리서치 인스티튜트 | 모듈 인식 도메인을 통한 항체 표적화 |
| US8574577B2 (en) | 2008-01-03 | 2013-11-05 | The Scripps Research Institute | VEGF antibodies comprising modular recognition domains |
| US8557242B2 (en) | 2008-01-03 | 2013-10-15 | The Scripps Research Institute | ERBB2 antibodies comprising modular recognition domains |
| US8557243B2 (en) | 2008-01-03 | 2013-10-15 | The Scripps Research Institute | EFGR antibodies comprising modular recognition domains |
| EA020954B1 (ru) | 2008-06-16 | 2015-03-31 | Бинд Терапьютикс, Инк. | Загруженные лекарственным средством полимерные наночастицы, фармацевтическая композиция и способ лечения рака |
| WO2010005726A2 (fr) * | 2008-06-16 | 2010-01-14 | Bind Biosciences Inc. | Nanoparticules polymères thérapeutiques avec inhibiteurs de mtor et procédés de fabrication et d’utilisation associés |
| US8318211B2 (en) | 2008-06-16 | 2012-11-27 | Bind Biosciences, Inc. | Therapeutic polymeric nanoparticles comprising vinca alkaloids and methods of making and using same |
| MX2011005051A (es) * | 2008-11-17 | 2011-06-01 | Genentech Inc | Metodo y formulacion para reducir la agregacion de una macromolecula bajo condiciones fisiologicas. |
| RU2011126338A (ru) * | 2008-11-28 | 2013-01-10 | Эбботт Лэборетриз | Стабильные композиции антител и способы их стабилизации |
| US8563041B2 (en) * | 2008-12-12 | 2013-10-22 | Bind Therapeutics, Inc. | Therapeutic particles suitable for parenteral administration and methods of making and using same |
| JP2012512175A (ja) | 2008-12-15 | 2012-05-31 | バインド バイオサイエンシズ インコーポレイテッド | 治療薬を徐放するための長時間循環性ナノ粒子 |
| WO2010081004A1 (fr) | 2009-01-09 | 2010-07-15 | Seattle Genetics, Inc. | Régimes posologiques hebdomadaires pour des conjugués anticorps anti-cd30 vc-pab-mmae - médicament |
| CA2748889A1 (fr) | 2009-03-18 | 2010-09-23 | Armagen Technologies, Inc. | Compositions et procedes pour le transport de proteines de fusion igg-recepteur leurre a travers la barriere hemato-encephalique |
| AR076284A1 (es) | 2009-04-29 | 2011-06-01 | Bayer Schering Pharma Ag | Inmunoconjugados de antimesotelina y usos de los mismos |
| US20100278822A1 (en) * | 2009-05-04 | 2010-11-04 | Abbott Biotechnology, Ltd. | Stable high protein concentration formulations of human anti-tnf-alpha-antibodies |
| PL2434886T3 (pl) | 2009-05-29 | 2020-05-18 | Cydex Pharmaceuticals, Inc. | Kompozycje do wstrzykiwania melfalanu zawierające pochodną cyklodekstryny i sposoby ich wytwarzania i stosowania |
| US11020363B2 (en) | 2009-05-29 | 2021-06-01 | Cydex Pharmaceuticals, Inc. | Injectable nitrogen mustard compositions comprising a cyclodextrin derivative and methods of making and using the same |
| SG10201810743WA (en) | 2009-06-03 | 2018-12-28 | Immunogen Inc | Conjugation methods |
| NZ713967A (en) | 2009-07-28 | 2017-01-27 | Shire Human Genetic Therapies | Compositions and methods for treating gaucher disease |
| US20110076232A1 (en) * | 2009-09-29 | 2011-03-31 | Ludwig Institute For Cancer Research | Specific binding proteins and uses thereof |
| EP2485761B1 (fr) | 2009-10-09 | 2019-02-27 | Armagen, Inc. | Procédés et compositions destinés à augmenter l'activité iduronate 2-sulfatase dans le snc |
| DK2509634T3 (en) | 2009-12-11 | 2019-04-23 | Pfizer | Stable formulations for lyophilization of therapeutic particles |
| EP2515942B1 (fr) | 2009-12-15 | 2020-02-12 | Pfizer Inc. | Compositions de nanoparticules polymères à visée thérapeutique à base de copolymères à température de transition vitreuse élevée ou poids moléculaires élevés |
| PH12012501364A1 (en) | 2010-01-15 | 2012-10-22 | Amgen K A Inc | Antibody formulation and therapeutic regimens |
| KR20130009760A (ko) | 2010-02-10 | 2013-01-23 | 이뮤노젠 아이엔씨 | Ｃｄ２０ 항체 및 이의 용도 |
| PT3345615T (pt) | 2010-03-01 | 2020-01-17 | Bayer Healthcare Llc | Anticorpos monoclonais otimizados contra inibidor da via do fator tecidual (tfpi) |
| EP2550018B1 (fr) * | 2010-03-22 | 2019-02-27 | F.Hoffmann-La Roche Ag | Compositions et méthodes pour la stabilisation de formulations contenant une protéine |
| WO2012009705A1 (fr) | 2010-07-15 | 2012-01-19 | Zyngenia, Inc. | Complexes liant ang-2 et leurs utilisations |
| US20120076779A1 (en) * | 2010-09-17 | 2012-03-29 | Baxter Healthcare S.A. | STABILIZATION OF IMMUNOGLOBULINS AND OTHER PROTEINS THROUGH AQUEOUS FORMULATIONS WITH SODIUM CHLORIDE AT WEAK ACIDIC TO NEUTRAL ph |
| US8821865B2 (en) | 2010-11-11 | 2014-09-02 | Abbvie Biotechnology Ltd. | High concentration anti-TNFα antibody liquid formulations |
| EP2672982B1 (fr) * | 2011-02-09 | 2019-09-04 | The Scripps Research Institute | Immunoconjugués d'haptène polypeptidique mimétique de ghreline ayant une solubilité et une immunogénéicité améliorées et leurs procédés d'utilisation |
| EP2500035A1 (fr) * | 2011-03-15 | 2012-09-19 | Icon Genetics GmbH | Formule pharmaceutique contenant de l'immunoglobuline |
| ME03353B (fr) | 2011-03-29 | 2019-10-20 | Immunogen Inc | Préparation de conjugués de maytansinoïde anticorps par procédé en une étape |
| PT2691112T (pt) | 2011-03-31 | 2018-07-10 | Merck Sharp & Dohme | Formulações estáveis de anticorpos para o recetor pd-1 humano de morte programada e tratamentos relacionados |
| EP2714738B1 (fr) | 2011-05-24 | 2018-10-10 | Zyngenia, Inc. | Complexes plurispécifiques multivalents et monovalents, et leurs utilisations |
| MX353958B (es) | 2011-09-22 | 2018-02-07 | Amgen Inc | Proteinas de union al antigeno cd27l. |
| AU2012346448B2 (en) | 2011-12-02 | 2017-09-14 | Armagen, Inc. | Methods and compositions for increasing arylsulfatase A activity in the CNS |
| AR091069A1 (es) | 2012-05-18 | 2014-12-30 | Amgen Inc | Proteinas de union a antigeno dirigidas contra el receptor st2 |
| EP2877589B1 (fr) | 2012-07-26 | 2024-03-06 | Momenta Pharmaceuticals, Inc. | Glycoprotéines ayant des propriétés anti-inflammatoires |
| US9592297B2 (en) | 2012-08-31 | 2017-03-14 | Bayer Healthcare Llc | Antibody and protein formulations |
| WO2014043618A1 (fr) | 2012-09-17 | 2014-03-20 | Bind Therapeutics, Inc. | Procédé de préparation de nanoparticules thérapeutiques |
| RU2661083C2 (ru) | 2012-10-04 | 2018-07-11 | Иммуноджен, Инк. | Использование пвдф-мембраны для очистки конъюгатов клеточно-связывающий агент - цитотоксический агент |
| WO2014089177A2 (fr) | 2012-12-04 | 2014-06-12 | Massachusetts Institute Of Technology | Composés, conjugués et compositions d'épipolythiodicétopipérazines et de polythiodicétopipérazines |
| TW201425336A (zh) | 2012-12-07 | 2014-07-01 | Amgen Inc | Ｂｃｍａ抗原結合蛋白質 |
| UA117466C2 (uk) | 2012-12-13 | 2018-08-10 | Мерк Шарп Енд Доме Корп. | СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19 |
| EP2948478B1 (fr) | 2013-01-25 | 2019-04-03 | Amgen Inc. | Anticorps ciblant cdh19 pour un mélanome |
| AU2014248640B2 (en) | 2013-03-13 | 2018-03-01 | Seagen Inc. | Cyclodextrin and antibody-drug conjugate formulations |
| US10150800B2 (en) | 2013-03-15 | 2018-12-11 | Zyngenia, Inc. | EGFR-binding modular recognition domains |
| WO2014186310A1 (fr) | 2013-05-13 | 2014-11-20 | Momenta Pharmaceuticals, Inc. | Méthodes de traitement de la neurodégénérescence |
| HUE056580T2 (hu) | 2013-05-30 | 2022-02-28 | Kiniksa Pharmaceuticals Ltd | Onkosztatin-M-receptor antigénjét kötõ fehérjék |
| TW201605896A (zh) | 2013-08-30 | 2016-02-16 | 安美基股份有限公司 | Gitr抗原結合蛋白 |
| WO2015059147A1 (fr) * | 2013-10-25 | 2015-04-30 | Bayer Pharma Aktiengesellschaft | Nouvelle formulation stable |
| SI3071237T1 (sl) * | 2013-11-21 | 2024-11-29 | Genmab A/S | Liofilizirana formulacija konjugata protitelo-zdravilo |
| PE20170312A1 (es) | 2014-03-14 | 2017-03-30 | Pfizer | Nanoparticulas terapeuticas que comprenden un agente terapeutico, y metodos para su elaboracion y uso |
| JP2015209384A (ja) * | 2014-04-24 | 2015-11-24 | ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | 医薬製剤 |
| US10538589B2 (en) | 2015-01-14 | 2020-01-21 | Armagen Inc. | Methods and compositions for increasing N-acetylglucosaminidase (NAGLU) activity in the CNS using a fusion antibody comprising an anti-human insulin receptor antibody and NAGLU |
| WO2016180941A1 (fr) * | 2015-05-13 | 2016-11-17 | Sanofi | Compositions liquides pour conjugués médicament-anticorps anti-cd19 |
| CN114853873B (zh) | 2015-06-11 | 2025-01-28 | 格纳西尼有限公司 | 经修饰的白细胞介素-7蛋白及其用途 |
| EP3356415B1 (fr) | 2015-09-29 | 2024-05-01 | Amgen Inc. | Inhibiteurs de l'asgr pour réduire les taux de cholestérol |
| KR102386735B1 (ko) * | 2015-11-06 | 2022-04-14 | 주식회사 제넥신 | 변형된 인터루킨-7 융합 단백질의 제형 |
| US20170189548A1 (en) * | 2015-11-25 | 2017-07-06 | Immunogen, Inc. | Pharmaceutical formulations and methods of use thereof |
| US11357827B2 (en) | 2015-12-04 | 2022-06-14 | Genexine, Inc. | Method for preventing or treating influenza virus infection using pharmaceutical composition comprising immunoglobulin Fc-fused interleukin-7 fusion protein |
| US11708399B2 (en) | 2015-12-04 | 2023-07-25 | Genexine, Inc. | Pharmaceutical composition comprising immunoglobulin Fc-fused interleukin-7 fusion protein for preventing or treating human papillomavirus-caused diseases |
| CN115400220A (zh) | 2015-12-30 | 2022-11-29 | 豪夫迈·罗氏有限公司 | 减少聚山梨酯降解的制剂 |
| KR20180101479A (ko) | 2016-01-13 | 2018-09-12 | 젠맵 에이/에스 | 항체 및 그의 약물 접합체를 위한 제제 |
| WO2017197045A1 (fr) | 2016-05-11 | 2017-11-16 | Movassaghi Mohammad | Synthèse totale convergente et énantiosélective d'analogues de la communesine |
| TWI780082B (zh) | 2016-11-18 | 2022-10-11 | 日商安斯泰來製藥股份有限公司 | 新穎抗人類ＭＵＣ１抗體Ｆａｂ片段 |
| WO2018158716A1 (fr) * | 2017-03-02 | 2018-09-07 | Cadila Healthcare Limited | Nouvelle formulation de conjugué protéine-médicament |
| US10799597B2 (en) | 2017-04-03 | 2020-10-13 | Immunomedics, Inc. | Subcutaneous administration of antibody-drug conjugates for cancer therapy |
| JP7382232B2 (ja) | 2017-05-02 | 2023-11-16 | メルク・シャープ・アンド・ドーム・エルエルシー | 抗ｌａｇ３抗体の製剤および抗ｌａｇ３抗体と抗ｐｄ－１抗体との共製剤 |
| JOP20190260A1 (ar) | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها |
| US11932650B2 (en) | 2017-05-11 | 2024-03-19 | Massachusetts Institute Of Technology | Potent agelastatin derivatives as modulators for cancer invasion and metastasis |
| TWI795415B (zh) | 2017-07-07 | 2023-03-11 | 日商安斯泰來製藥股份有限公司 | 新穎的抗人類ＣＥＡＣＡＭ５抗體Ｆａｂ片段 |
| AU2018320470B2 (en) | 2017-08-23 | 2025-04-24 | Daiichi Sankyo Company, Limited | Antibody-drug conjugate preparation and lyophilization for same |
| IL324591A (en) | 2017-08-31 | 2026-01-01 | Daiichi Sankyo Co Ltd | Improved antibody-drug conjugate production methods |
| US10640508B2 (en) | 2017-10-13 | 2020-05-05 | Massachusetts Institute Of Technology | Diazene directed modular synthesis of compounds with quaternary carbon centers |
| GB201719447D0 (en) | 2017-11-23 | 2018-01-10 | Ucb Biopharma Sprl | Pharmaceutical composition |
| TWI841554B (zh) | 2018-03-21 | 2024-05-11 | 丹麥商珍美寶股份有限公司 | 以鉑為主之劑與抗組織因子抗體－藥物共軛物的組合治療癌症之方法 |
| CR20250325A (es) * | 2018-04-13 | 2025-08-29 | Genentech Inc | Formulaciones inmunoconjugadas anti-cd79b estables (divisional expediente 2020-0550) |
| TW202506732A (zh) | 2018-05-07 | 2025-02-16 | 丹麥商珍美寶股份有限公司 | 使用抗ｐｄ－１抗體與抗組織因子抗體－藥物共軛體之組合以治療癌症之方法 |
| BR112020023420A8 (pt) | 2018-05-17 | 2022-07-05 | Astellas Pharma Inc | Complexo tendo fragmento fab de anticorpo anti-muc1 humano, peptídeo ligador e/ou ligante |
| SG11202103670XA (en) | 2018-10-10 | 2021-05-28 | Astellas Pharma Inc | Pharmaceutical composition containing tagged site-antihuman antibody fab fragment complex |
| WO2020081408A1 (fr) | 2018-10-18 | 2020-04-23 | Merck Sharp & Dohme Corp. | Formulations d'anticorps anti-rsv et leurs procédés d'utilisation |
| TWI844571B (zh) | 2018-10-30 | 2024-06-11 | 丹麥商珍美寶股份有限公司 | 使用抗血管內皮生長因子（ｖｅｇｆ）抗體與抗組織因子（ｔｆ）抗體－藥物共軛體之組合以治療癌症之方法 |
| MX2021004928A (es) | 2018-10-31 | 2021-06-08 | Merck Sharp & Dohme Llc | Cristales de anticuerpo anti-pd-1 humano y metodos de uso de los mismos. |
| EP3876990A4 (fr) | 2018-11-07 | 2023-09-06 | Merck Sharp & Dohme LLC | Co-formulations d'anticorps anti-lag3 et d'anticorps anti-pd-1 |
| CN120241997A (zh) | 2019-02-18 | 2025-07-04 | 伊莱利利公司 | 治疗性抗体制剂 |
| EA202192860A1 (ru) * | 2019-04-18 | 2021-12-23 | Янссен Байотек, Инк | Сиалилированные гликопротеины |
| WO2020234114A1 (fr) | 2019-05-21 | 2020-11-26 | Bayer Aktiengesellschaft | Nouvelle formulation stable à haute concentration pour anetumab ravtansine |
| US11535634B2 (en) | 2019-06-05 | 2022-12-27 | Massachusetts Institute Of Technology | Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof |
| CN119679936A (zh) * | 2019-06-24 | 2025-03-25 | 诺华股份有限公司 | 针对靶向b细胞成熟抗原的多特异性抗体的给药方案和组合疗法 |
| BR112022019073A2 (pt) * | 2020-03-25 | 2022-11-08 | Jiangsu Hengrui Pharmaceuticals Co Ltd | Composição farmacêutica que compreende conjugado anticorpo-fármaco e uso da mesma |
| CN111879930A (zh) * | 2020-08-04 | 2020-11-03 | 上海艾瑞德生物科技有限公司 | 肌酸激酶同工酶mb检测试剂盒及其制备方法 |
| EP4192511A1 (fr) | 2020-08-07 | 2023-06-14 | Fortis Therapeutics, Inc. | Immunoconjugués ciblant cd46 et procédés d'utilisation associés |
| WO2022182415A1 (fr) | 2021-02-24 | 2022-09-01 | Massachusetts Institute Of Technology | Dérivés d'himastatine, leurs procédés de préparation et leurs utilisations |
| WO2025064944A1 (fr) * | 2023-09-20 | 2025-03-27 | Vor Biopharma Inc. | Compositions pharmaceutiques de conjugués anticorps-médicament anti-cd45 |
Family Cites Families (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3890238A (en) * | 1972-12-21 | 1975-06-17 | Basf Wyandotte Corp | Water solubility of polyoxyalkylene polymers |
| US3896111A (en) * | 1973-02-20 | 1975-07-22 | Research Corp | Ansa macrolides |
| US4151042A (en) * | 1977-03-31 | 1979-04-24 | Takeda Chemical Industries, Ltd. | Method for producing maytansinol and its derivatives |
| US4563304A (en) * | 1981-02-27 | 1986-01-07 | Pharmacia Fine Chemicals Ab | Pyridine compounds modifying proteins, polypeptides or polysaccharides |
| US4597966A (en) * | 1985-01-09 | 1986-07-01 | Ortho Diagnostic Systems, Inc. | Histidine stabilized immunoglobulin and method of preparation |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5225539A (en) * | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5208020A (en) * | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| US5196193A (en) * | 1989-10-31 | 1993-03-23 | Ophidian Pharmaceuticals, Inc. | Antivenoms and methods for making antivenoms |
| ATE158021T1 (de) * | 1990-08-29 | 1997-09-15 | Genpharm Int | Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper |
| US5545806A (en) * | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| EP0563475B1 (fr) * | 1992-03-25 | 2000-05-31 | Immunogen Inc | Conjugués d'agents ciblés et de dérivés du CC-1065 |
| US5639641A (en) * | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| IL111748A0 (en) * | 1993-12-03 | 1995-01-24 | Zeneca Ltd | Proteins |
| US6265150B1 (en) * | 1995-06-07 | 2001-07-24 | Becton Dickinson & Company | Phage antibodies |
| ES2434840T3 (es) * | 1995-07-27 | 2013-12-17 | Genentech, Inc. | Formulación de proteína liofilizada isotónica estable |
| US6267958B1 (en) * | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| US5714352A (en) * | 1996-03-20 | 1998-02-03 | Xenotech Incorporated | Directed switch-mediated DNA recombination |
| US6306393B1 (en) * | 1997-03-24 | 2001-10-23 | Immunomedics, Inc. | Immunotherapy of B-cell malignancies using anti-CD22 antibodies |
| CA2635352C (fr) * | 1997-06-13 | 2012-09-11 | Genentech, Inc. | Formulation stabilisee renfermant un anticorps |
| US6171586B1 (en) * | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
| US7067109B1 (en) | 1998-07-13 | 2006-06-27 | Board Of Regents, The University Of Texas System | Cancer treatment kits comprising therapeutic conjugates that bind to aminophospholipids |
| BR0012196A (pt) | 1999-06-25 | 2002-03-19 | Genentech Inc | Método de tratamento de um tumor em mamìferos através do uso de conjugados de maitansinóide e anticorpo receptor anti-erbb e artigo industrializado |
| KR20020063163A (ko) | 1999-09-22 | 2002-08-01 | 가네가후치 가가쿠 고교 가부시키가이샤 | 신규 빵 효모 및 그 효모를 함유하는 밀가루 반죽 |
| AU775373B2 (en) | 1999-10-01 | 2004-07-29 | Immunogen, Inc. | Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents |
| US6824780B1 (en) * | 1999-10-29 | 2004-11-30 | Genentech, Inc. | Anti-tumor antibody compositions and methods of use |
| ES2309012T3 (es) | 1999-10-29 | 2008-12-16 | Genentech, Inc. | Composiciones del anticuerpo anti-psca y a sus procedimientos contra celulas cancerigenas que expresen psca. |
| US20020028178A1 (en) * | 2000-07-12 | 2002-03-07 | Nabil Hanna | Treatment of B cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications |
| CA2388063C (fr) * | 1999-11-24 | 2010-06-08 | Immunogen, Inc. | Agents cytotoxiques comprenant des taxanes et leur utilisation therapeutique |
| AU767394C (en) * | 1999-12-29 | 2005-04-21 | Immunogen, Inc. | Cytotoxic agents comprising modified doxorubicins and daunorubicins and their therapeutic use |
| WO2001058479A1 (fr) * | 2000-02-08 | 2001-08-16 | The Penn State Research Foundation | Utilisation du recepteur de l'interleukine 13, sous-unite alpha 2, dans l'immunotherapie |
| US7097840B2 (en) * | 2000-03-16 | 2006-08-29 | Genentech, Inc. | Methods of treatment using anti-ErbB antibody-maytansinoid conjugates |
| BR0111948A (pt) * | 2000-06-26 | 2004-08-24 | Rxkinetix Inc | Composição para entrega de fator de crescimento hematopoiético |
| JP5485489B2 (ja) | 2000-08-11 | 2014-05-07 | 中外製薬株式会社 | 抗体含有安定化製剤 |
| US6596503B1 (en) | 2000-08-18 | 2003-07-22 | East Carolina University | Monoclonal antibody DS6, tumor-associated antigen CA6, and methods of use thereof |
| US6333410B1 (en) * | 2000-08-18 | 2001-12-25 | Immunogen, Inc. | Process for the preparation and purification of thiol-containing maytansinoids |
| NZ527283A (en) | 2001-01-29 | 2006-03-31 | Biogen Idec Inc | Modified antibodies and methods of use |
| KR100863624B1 (ko) | 2001-05-11 | 2008-10-15 | 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 | Ｃｄ26을 발현하는 세포와 연관된 질환의 치료제로사용되는 항-ｃｄ26 단클론항체 |
| US6441163B1 (en) * | 2001-05-31 | 2002-08-27 | Immunogen, Inc. | Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents |
| MXPA04000747A (es) | 2001-07-25 | 2004-07-08 | Protein Desing Labs Inc | Formulacion farmaceutica liofilizada estable de anticuerpos igg. |
| IL161677A0 (en) * | 2001-11-08 | 2004-09-27 | Protein Design Labs | Stable liquid pharmaceutical formulation of igg antibodies |
| US6716821B2 (en) * | 2001-12-21 | 2004-04-06 | Immunogen Inc. | Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same |
| AU2003201824A1 (en) | 2002-01-03 | 2003-07-24 | Smithkline Beecham Corporation | Methods for preparing immunoconjugates |
| US6756397B2 (en) * | 2002-04-05 | 2004-06-29 | Immunogen, Inc. | Prodrugs of CC-1065 analogs |
| US6596757B1 (en) | 2002-05-14 | 2003-07-22 | Immunogen Inc. | Cytotoxic agents comprising polyethylene glycol-containing taxanes and their therapeutic use |
| AU2002304965A1 (en) * | 2002-05-24 | 2003-12-12 | Zensun (Shanghai) Sci-Tech.Ltd | Neuregulin based methods and compositions for treating viral myocarditis and dilated cardiomyopathy |
| US6982253B2 (en) * | 2002-06-05 | 2006-01-03 | Supergen, Inc. | Liquid formulation of decitabine and use of the same |
| US7132100B2 (en) * | 2002-06-14 | 2006-11-07 | Medimmune, Inc. | Stabilized liquid anti-RSV antibody formulations |
| CN1671741A (zh) * | 2002-06-21 | 2005-09-21 | 拜奥根Idec公司 | 浓缩抗体的缓冲剂制剂及其使用方法 |
| JP2005532395A (ja) * | 2002-07-02 | 2005-10-27 | スミスクライン・ビーチャム・コーポレイション | 新規な安定処方 |
| EP1391213A1 (fr) * | 2002-08-21 | 2004-02-25 | Boehringer Ingelheim International GmbH | Compositions et méthodes pour le traitement du cancer en utilisant un conjugué d'un anticorps contre le CD44 avec un maytansinoide et des agents chimiothérapeutiques |
| US20040126379A1 (en) * | 2002-08-21 | 2004-07-01 | Boehringer Ingelheim International Gmbh | Compositions and methods for treating cancer using cytotoxic CD44 antibody immunoconjugates and chemotherapeutic agents |
| WO2004019860A2 (fr) * | 2002-08-28 | 2004-03-11 | Pharmacia Corporation | Formulations d'anticorps modifies et procedes de fabrication de telles formulations |
| WO2004060343A1 (fr) | 2002-12-31 | 2004-07-22 | Nektar Therapeutics | Particules contenant des anticorps et compositions |
| AU2004207003A1 (en) | 2003-01-30 | 2004-08-12 | Medimmune, Llc | Anti-integrin alphanubeta3 antibody formulations and uses thereof |
| EP2481819A1 (fr) | 2003-02-25 | 2012-08-01 | MedImmune Vaccines, Inc. | Filtration á contra courant dans la production de compositions du vaccins d'influenza stabilisées |
| CN1816356A (zh) * | 2003-05-14 | 2006-08-09 | 免疫原公司 | 药物缀合物组合物 |
| GB0317509D0 (en) * | 2003-07-25 | 2003-08-27 | Pfizer Ltd | Nicotinamide derivatives useful as PDE4 inhibitors |
| US7404957B2 (en) * | 2003-08-29 | 2008-07-29 | Aerovance, Inc. | Modified IL-4 mutein receptor antagonists |
| TW200517114A (en) * | 2003-10-15 | 2005-06-01 | Combinatorx Inc | Methods and reagents for the treatment of immunoinflammatory disorders |
| DE10361599A1 (de) | 2003-12-24 | 2005-07-28 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Flüssigformulierung von Antikörperkonjugaten |
| AR046774A1 (es) | 2003-12-24 | 2005-12-21 | Boehringer Ingelheim Pharma | Formulacion liofilizada de conjugados de anticuerpos |
-
2006
- 2006-08-02 WO PCT/US2006/030295 patent/WO2007019232A2/fr not_active Ceased
- 2006-08-02 CA CA 2615122 patent/CA2615122A1/fr not_active Abandoned
- 2006-08-02 NZ NZ623901A patent/NZ623901A/en not_active IP Right Cessation
- 2006-08-02 NZ NZ564843A patent/NZ564843A/en not_active IP Right Cessation
- 2006-08-02 MX MX2008001492A patent/MX336033B/es unknown
- 2006-08-02 EA EA200800233A patent/EA014513B1/ru unknown
- 2006-08-02 NZ NZ59917606A patent/NZ599176A/en not_active IP Right Cessation
- 2006-08-02 AU AU2006278573A patent/AU2006278573A1/en not_active Abandoned
- 2006-08-02 KR KR1020087002609A patent/KR101566393B1/ko not_active Expired - Fee Related
- 2006-08-02 JP JP2008525189A patent/JP2009503105A/ja active Pending
- 2006-08-02 EP EP06800717A patent/EP1917030A4/fr not_active Withdrawn
- 2006-08-02 BR BRPI0614100-5A patent/BRPI0614100A2/pt not_active Application Discontinuation
- 2006-08-03 US US11/498,139 patent/US9114179B2/en not_active Expired - Fee Related
-
2008
- 2008-01-13 IL IL188733A patent/IL188733A/en not_active IP Right Cessation
- 2008-02-01 NO NO20080612A patent/NO20080612L/no not_active Application Discontinuation
- 2008-02-06 EC ECSP088159 patent/ECSP088159A/es unknown
-
2012
- 2012-06-20 JP JP2012138483A patent/JP2012211163A/ja not_active Withdrawn
-
2015
- 2015-08-07 JP JP2015157269A patent/JP6389446B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EA200800233A1 (ru) | 2008-08-29 |
| EP1917030A2 (fr) | 2008-05-07 |
| NZ599176A (en) | 2014-04-30 |
| US9114179B2 (en) | 2015-08-25 |
| EP1917030A4 (fr) | 2011-03-09 |
| JP6389446B2 (ja) | 2018-09-12 |
| JP2012211163A (ja) | 2012-11-01 |
| MX336033B (es) | 2016-01-07 |
| WO2007019232A2 (fr) | 2007-02-15 |
| MX2008001492A (es) | 2008-04-04 |
| US20070031402A1 (en) | 2007-02-08 |
| KR20080033324A (ko) | 2008-04-16 |
| CA2615122A1 (fr) | 2007-02-15 |
| IL188733A0 (en) | 2008-08-07 |
| NZ623901A (en) | 2015-10-30 |
| KR101566393B1 (ko) | 2015-11-05 |
| IL188733A (en) | 2015-05-31 |
| EA014513B1 (ru) | 2010-12-30 |
| AU2006278573A1 (en) | 2007-02-15 |
| NZ564843A (en) | 2012-05-25 |
| ECSP088159A (es) | 2008-03-26 |
| WO2007019232A3 (fr) | 2007-06-28 |
| JP2009503105A (ja) | 2009-01-29 |
| JP2016020359A (ja) | 2016-02-04 |
| BRPI0614100A2 (pt) | 2011-03-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20080612L (no) | Immunokonjugatpreparater | |
| NO20075693L (no) | Modulerende forbindelser av indolamin-2,3-dioksygenase og fremgangsmater for anvendelse av samme | |
| NO20081889L (no) | Fast vaksine formulering | |
| NO20074238L (no) | Fiksert dosering av HER-antistoffer | |
| NO20081576L (no) | Preparater og fremgangsmater for fremstilling av darlig vannloselige legemidler med okt stabilitet | |
| PY0723043A (es) | Derivados de N-(Amino-heteroaril)-1H-Indol-2-carboxamidas, su preparación y su aplicación en terapéutica. | |
| NO20082124L (no) | Bifenyloksyeddiksyrederivater for behandling av respiratorisk sykdom | |
| CY1109998T1 (el) | Ενδυναμωτες υποδοχεων γλουταμινικου | |
| EA200700168A1 (ru) | Производные замещенной циклической мочевины, их получение и их фармацевтическое применение в качестве ингибиторов киназы | |
| NO20054185D0 (no) | Methods of radiofluorination of biologically active vectors | |
| DK2315580T3 (da) | Farmaceutiske formuleringer og fremgangsmåder til behandling af luftvejsinfektioner | |
| NO20034660L (no) | Spiropyrazolforbindelser, farmasoytiske preparater som omfatter en slik forbindelse, og anvendelse av forbindelsene for fremstilling av farmasoytiske preparater | |
| NO20070487L (no) | 3-aminocyklopentankarboksamider som modulatorer av kjemokinreseptorer. | |
| NO20091395L (no) | Nye tiofenderivater | |
| BR0212922A (pt) | Composições farmacêuticas | |
| NO20083104L (no) | Fast preparat | |
| EA200700489A1 (ru) | Новые бензоконденсированные гетероарилсульфамидные производные, полезные в качестве противоконвульсивных средств | |
| NO20082285L (no) | 3-aminosyklopentankarboksamider som modulatorer av kjemokinreseptorer | |
| EA202091398A1 (ru) | Составы вакцинных композиций от вируса денге | |
| NO20065701L (no) | Orodispersibel farmasoytisk sammensetning for oromukosal eller sublingval administrasjon av agomelatin | |
| NO20075985L (no) | Stabil emulsjonsforbindelse | |
| NO20090764L (no) | 4-hydroksytiobenzamidderivater og legemidler | |
| NO20071840L (no) | Ikke-peptid bradykininantagonister og farmasoytiske sammensetninger derav. | |
| DK1517890T3 (da) | Kationisk substituerede diphenylazetidinoner, fremgangsmåde til deres fremstilling, lægemidler indeholdende disse forbindelser og deres anvendelse | |
| DK1456212T3 (da) | 6-aminomorphinanderivater, fremgangsmåder til fremstilling heraf og disses anvendelse |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |